Avanos Medical Statistics
Total Valuation
Avanos Medical has a market cap or net worth of $771.29 million. The enterprise value is $884.49 million.
Important Dates
The last earnings date was Wednesday, October 30, 2024, before market open.
| Earnings Date | Oct 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Avanos Medical has 43.16 million shares outstanding. The number of shares has decreased by -0.32% in one year.
| Current Share Class | 43.16M |
| Shares Outstanding | 43.16M |
| Shares Change (YoY) | -0.32% |
| Shares Change (QoQ) | +0.65% |
| Owned by Insiders (%) | 1.53% |
| Owned by Institutions (%) | 94.06% |
| Float | 39.30M |
Valuation Ratios
The trailing PE ratio is 52.44 and the forward PE ratio is 11.43. Avanos Medical's PEG ratio is 0.54.
| PE Ratio | 52.44 |
| Forward PE | 11.43 |
| PS Ratio | 1.21 |
| Forward PS | 1.06 |
| PB Ratio | 0.67 |
| P/TBV Ratio | 3.60 |
| P/FCF Ratio | 21.07 |
| P/OCF Ratio | 13.90 |
| PEG Ratio | 0.54 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.44, with an EV/FCF ratio of 24.17.
| EV / Earnings | 56.34 |
| EV / Sales | 1.30 |
| EV / EBITDA | 8.44 |
| EV / EBIT | 15.71 |
| EV / FCF | 24.17 |
Financial Position
The company has a current ratio of 2.22, with a Debt / Equity ratio of 0.16.
| Current Ratio | 2.22 |
| Quick Ratio | 1.04 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 1.69 |
| Debt / FCF | 5.52 |
| Interest Coverage | 4.43 |
Financial Efficiency
Return on equity (ROE) is 1.77% and return on invested capital (ROIC) is 2.38%.
| Return on Equity (ROE) | 1.77% |
| Return on Assets (ROA) | 2.08% |
| Return on Capital (ROIC) | 2.38% |
| Revenue Per Employee | $180,721 |
| Profits Per Employee | $4,163 |
| Employee Count | 3,771 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 1.90 |
Taxes
In the past 12 months, Avanos Medical has paid $4.40 million in taxes.
| Income Tax | 4.40M |
| Effective Tax Rate | 16.86% |
Stock Price Statistics
The stock price has decreased by -16.81% in the last 52 weeks. The beta is 0.93, so Avanos Medical's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | -16.81% |
| 50-Day Moving Average | 21.95 |
| 200-Day Moving Average | 20.86 |
| Relative Strength Index (RSI) | 28.86 |
| Average Volume (20 Days) | 299,787 |
Short Selling Information
The latest short interest is 607,189, so 1.41% of the outstanding shares have been sold short.
| Short Interest | 607,189 |
| Short Previous Month | 761,755 |
| Short % of Shares Out | 1.41% |
| Short % of Float | 1.55% |
| Short Ratio (days to cover) | 3.15 |
Income Statement
In the last 12 months, Avanos Medical had revenue of $681.50 million and earned $15.70 million in profits. Earnings per share was $0.34.
| Revenue | 681.50M |
| Gross Profit | 378.30M |
| Operating Income | 56.30M |
| Pretax Income | 14.70M |
| Net Income | 15.70M |
| EBITDA | 104.80M |
| EBIT | 56.30M |
| Earnings Per Share (EPS) | $0.34 |
Full Income StatementBalance Sheet
The company has $89.00 million in cash and $202.20 million in debt, giving a net cash position of -$113.20 million or -$2.62 per share.
| Cash & Cash Equivalents | 89.00M |
| Total Debt | 202.20M |
| Net Cash | -113.20M |
| Net Cash Per Share | -$2.62 |
| Equity (Book Value) | 1.23B |
| Book Value Per Share | 26.73 |
| Working Capital | 259.70M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $55.50 million and capital expenditures -$18.90 million, giving a free cash flow of $36.60 million.
| Operating Cash Flow | 55.50M |
| Capital Expenditures | -18.90M |
| Free Cash Flow | 36.60M |
| FCF Per Share | $0.85 |
Full Cash Flow StatementMargins
Gross margin is 55.51%, with operating and profit margins of 8.26% and 2.30%.
| Gross Margin | 55.51% |
| Operating Margin | 8.26% |
| Pretax Margin | 3.83% |
| Profit Margin | 2.30% |
| EBITDA Margin | 15.38% |
| EBIT Margin | 8.26% |
| FCF Margin | 6.13% |